Kodiak Sciences Inc KOD

$99.87 +5.61 (5.95%)

Valuation

Market cap
5,924,146,000
Revenue TTM
$0
Net income TTM
$-229,970,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,735,300
Avg volume
1,874,632
Day's range
$93.70 – $100.33
Shares out
62,849,000
Stochastic %K
80%
Beta
2.03
Analysts
Strong Sell
Price target
$116.67

Price

Company profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical stu...

Show more

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 281 0850
Website
https://kodiak.com
Address
1250 Page Mill Road, Palo Alto, United States

Latest news

Stocktwits

gr8whitenorth Oct 10, 6:55 PM
$KOD I meant 100$ 😆🦍🚀🌚
0 replies
Serghei Oct 10, 2:44 PM
$KOD Tell me I'm wrong and back it up with arguments! While everyone hypes Kodiak’s Daybreak results, they ignore a critical reality: KOD’s drugs are unapproved, they have zero commercial network, and they are running out of cash. Meanwhile, Ocular Therapeutix ($OCUL) is already suffocating the competition: • Superior Efficacy: AXPAXLI achieved FDA-confirmed superiority in Phase 3 SOL-1 over market leader Eylea, not just "non-inferiority" like KOD. • Unrivaled Durability: Hydrogel tech delivers 9 to 12 months of control (1-2 shots/year). KOD only stretches to 5-6 months for just half of its patients. • Cash Fortress ($598.6M vs $125.9M): OCUL has a massive runway into 2028. KOD's cash barely scratches 2027, creating a severe dilution risk to fund any future launch. • Pre-Built Sales Machine: OCUL already has an active US sales force and distribution network (from Dextenza) expanding for AXPAXLI. KOD has zero commercial infrastructure and must build it from scratch.
6 replies
PaulThomasTPG Oct 10, 1:13 PM
$APP $META $KOD Almost everyone I know is saying this is a massive buying opportunity. After dropping a bit more last week, What do you think? https://youtu.be/uWmodE6lSdE
1 replies
JJenniferr Oct 9, 11:29 PM
$KOD high option volume on 90 put and 110 call Oct
0 replies
hp12349472 Oct 9, 10:42 PM
$KOD so whats the outcome of the presentations? Nothing?
2 replies
spinusn27 Oct 9, 10:31 PM
$KOD Do a little research on Baker Brothers and Seagen (SGEN). In 2023, Seagen was trading around $161 before Pfizer announced its $43B buyout at $229 per share. Baker Brothers walked away with roughly $10B. Not saying KOD is next, but these guys have a history worth looking into. 💎🙌
1 replies
AgentBlack Oct 9, 10:15 PM
$KOD Kodiak currently has no active salesforce or commercial distribution network. Lol.
1 replies
spinusn27 Oct 9, 9:56 PM
$KOD September 30 short interest is out! Shorts dropped from 10.67M to 9.38M shares, down almost 1.3M (12%). Interesting part is there are still over 9 million shares short, and KOD has been holding near $100. Makes me wonder how many more have covered since September 30. Next report should be interesting! Meanwhile, the bear army is still telling everyone to hold the line. 🤣💎🙌
2 replies